TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03381495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride, Sufentanil
Description: In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
Study: NCT03350646

Intervention type: OTHER
Group type: OTHER
Intervention: Volume of medium during embryo transfer

Intervention type: OTHER
Group type: OTHER
Intervention: Volume of medium during embryo transfer
Study: NCT02855372

Intervention type: PROCEDURE
Intervention: Lung transplantation
Study: NCT00730860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation associated with TACE
Description: treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation only
Description: treatment of hepatocellular carcinoma by radiofrequency ablation only
Study: NCT01379768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care Cleaning and Disinfection Solution
Description: Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care Cleaning and Disinfection Solution
Description: Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
Study: NCT03819712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of blood samples
Description: 23 mL of blood will be collected during the inclusion visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of blood samples
Description: 23 mL of blood will be collected during the inclusion visit
Study: NCT01963442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Lactams
Description: administered from Day 0 to Day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta-Lactams
Description: administered from Day 0 to Day 3
Study: NCT02149576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography Imaging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest Radiograph Imaging
Study: NCT01381614

Intervention type: DRUG
Intervention: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Study: NCT01514864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
Study: NCT04361916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care monitoring
Description: home care active monitoring of patients with suspected of confirmed COVID-19
Study: NCT03344913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: walking 30 minutes per day, three days/week for 6 weeks with a member of study team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
Study: NCT03377283

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: organ perfusion with rabbit anti-thymocyte globulin (rATG)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: organ perfusion with saline
Study: NCT01383616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)
Description: A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)
Description: A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
Study: NCT02841085

Intervention type: GENETIC
Intervention: Genetic sample
Description: Blood sample or saliva collection
Study: NCT03819712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of fecal samples
Description: Fecal sample self-collected after the inclusion visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of fecal samples
Description: Fecal sample self-collected after the inclusion visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine samples
Description: 10 mL of urine will be collected during the inclusion visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine samples
Description: 10 mL of urine will be collected during the inclusion visit
Study: NCT04747847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and anakinra
Description: Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
Study: NCT03340818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
Study: NCT02160561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
Study: NCT00614536

Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: 10mg - 20mg tablet once or twice daily for 12weeks
Study: NCT03819712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of vaginal swaps
Description: Sample of vaginal microbiota collected during the inclusion visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of vaginal swaps
Description: Sample of vaginal microbiota collected during the inclusion visit
Study: NCT03477539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study: NCT02222844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative MRI scan
Description: Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
Study: NCT03477539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT02754427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective Surveillance Group
Description: Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Group
Description: Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
Study: NCT02168257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAM Cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Binasal Prong CPAP
Study: NCT01256489

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
Study: NCT01975142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - Emtansine
Study: NCT02928653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
Study: NCT01666158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
Study: NCT03483233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI and EEG study
Description: fMRI and EEG study
Study: NCT04344028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: True Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a visual N-back task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: True Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a visual N-back task.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a knowledge task (control).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a knowledge task (control).
Study: NCT02396498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Using cisplatin in HIPEC plus oral S-1
Study: NCT03743987

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: a procedure used to prevent or resolves apical periodontitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA group
Description: a procedure used to prevent or resolves apical periodontitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF group
Description: a procedure that is used for wound healing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA + PRF group
Description: a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
Study: NCT01910740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity
Description: Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
Study: NCT04344028

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Negative Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
Study: NCT03074058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)
Description: Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
Description: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
Study: NCT00904358

Intervention type: DIAGNOSTIC_TEST
Intervention: cross sectional area
Study: NCT01910740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Interaction
Description: To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
Study: NCT02754752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture Therapy
Description: Undergo electroacupuncture therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture Therapy
Description: Undergo modified electroacupuncture therapy
Study: NCT01469130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
Study: NCT02754752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02274051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kinetin
Description: Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
Study: NCT00645320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
Study: NCT02683213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20mg once daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT00911183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated doxorubicin citrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00741689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
Study: NCT03985228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk
Description: Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo milk
Description: Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a.
Study: NCT01075100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: 20 mg/m2 on Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2.5 on Days 1 and 8
Study: NCT05071378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Family, Our Voices
Description: Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.